Expression and clinical significance of miR-421 in prostate cancer.

IF 2 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Biomarkers Pub Date : 2025-01-13 DOI:10.1080/1354750X.2024.2445804

Xiaojuan Huang, Guifang He, Lulu Zheng, Yongping Cai, Yu Yin

{"title":"Expression and clinical significance of miR-421 in prostate cancer.","authors":"Xiaojuan Huang, Guifang He, Lulu Zheng, Yongping Cai, Yu Yin","doi":"10.1080/1354750X.2024.2445804","DOIUrl":null,"url":null,"abstract":"Objective: To examine the role and diagnostic potential of miR-421 in prostate cancer (PCa).Methods: Expression data and clinical information for miR-421 were obtained from the TCGA and Genotype-Tissue Expression (GTEx) databases. Experimental validation was performed at the cellular, blood, and tissue levels to confirm miR-421 expression and its association with clinicopathological features. ROC curves were drawn on the bioinformatic study using TCGA data. The target genes of miR-421 were predicted via four online databases, and protein interaction associations were analyzed for intersecting targets. Gene Ontology (GO) analysis was subsequently conducted to assess functional relevance.Results: MiR-421 was significantly overexpressed in prostate cancer (PCa) patients, a finding validated in cell, blood, and tissue samples. ROC analysis on the bioinformatic study using TCGA data revealed that miR-421 reliably differentiated PCa tissues from normal tissues. Higher miR-421 expression was associated with an elevated Gleason score, advanced TNM stage, and metastasis. GO enrichment analysis indicated that the target genes of miR-421 were significantly related to diverse molecular functions.Conclusions: MiR-421 is a promising biomarker for diagnosing and predicting PCa.","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"1-9"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1354750X.2024.2445804","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To examine the role and diagnostic potential of miR-421 in prostate cancer (PCa).

Methods: Expression data and clinical information for miR-421 were obtained from the TCGA and Genotype-Tissue Expression (GTEx) databases. Experimental validation was performed at the cellular, blood, and tissue levels to confirm miR-421 expression and its association with clinicopathological features. ROC curves were drawn on the bioinformatic study using TCGA data. The target genes of miR-421 were predicted via four online databases, and protein interaction associations were analyzed for intersecting targets. Gene Ontology (GO) analysis was subsequently conducted to assess functional relevance.

Results: MiR-421 was significantly overexpressed in prostate cancer (PCa) patients, a finding validated in cell, blood, and tissue samples. ROC analysis on the bioinformatic study using TCGA data revealed that miR-421 reliably differentiated PCa tissues from normal tissues. Higher miR-421 expression was associated with an elevated Gleason score, advanced TNM stage, and metastasis. GO enrichment analysis indicated that the target genes of miR-421 were significantly related to diverse molecular functions.

Conclusions: MiR-421 is a promising biomarker for diagnosing and predicting PCa.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers 医学-毒理学

CiteScore

5.00

自引率

3.80%

发文量

140

审稿时长

3 months

期刊介绍： The journal Biomarkers brings together all aspects of the rapidly growing field of biomarker research, encompassing their various uses and applications in one essential source. Biomarkers provides a vital forum for the exchange of ideas and concepts in all areas of biomarker research. High quality papers in four main areas are accepted and manuscripts describing novel biomarkers and their subsequent validation are especially encouraged: • Biomarkers of disease • Biomarkers of exposure • Biomarkers of response • Biomarkers of susceptibility Manuscripts can describe biomarkers measured in humans or other animals in vivo or in vitro. Biomarkers will consider publishing negative data from studies of biomarkers of susceptibility in human populations.